X

Drug Profile

Enibarcimab - Adrenomed

Alternative Names: Adrecizumab - Adrenomed; HAM 8101

Latest Information Update: 11 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adrenomed
Class Anti-infectives; Antivirals; Heart failure therapies; Monoclonal antibodies
Mechanism of Action Adrenomedullin modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Acute heart failure; COVID 2019 infections; Septic shock

Most Recent Events

10 Apr 2024 Enibarcimab receives fast track status for Septic Shock in USA
10 Apr 2024 AdrenoMed plans a phase IIb/III trial for septic shock in
15 Nov 2023 University Medical Center Hamburg-Eppendorf terminates the phase II trial in COVID-2019 infections in Germany (IV) due to poor recruitment (NCT05156671) (EudraCT2020-001336-10)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Market Movers of 2025 Webinar

This session is built around insights from our in-depth analysis of drug candidates and market shifts expected to shape the pharmaceutical landscape in 2025. We’ll explore two transformative categories (1) Groundbreaking Drug Launches and (2) Patent Expiration & Market Impact. This webinar will also focus on pivotal clinical trials and regulatory milestones, showcasing how data-driven strategies are shaping the development and approval of these market movers.